Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. (ESPR) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ESPR · as of Mar 31, 2025
Ownership Breakdown
191
Institutional Holders
▼ 16 vs Q4
$171.59M
Total Inst. Value
▼ $106.34M vs Q4
207.91M
Shares Outstanding
freeFloat 100.00%
113.64M
13F Shares Held
▼ 12.71M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ESPR largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. pharmaceutical preparations | 14.49M | 7.39% | 7.39% | $20.87B | May 2, 2025 | ▲ 257.6K |
VANGUARD GROUP INC pharmaceutical preparations | 11.49M | 5.86% | 5.86% | $16.54B | May 9, 2025 | ▼ 228.0K |
WASATCH ADVISORS LP pharmaceutical preparations | 10.93M | 5.57% | 5.57% | $15.74B | May 15, 2025 | ▼ 13.55M |
BELLEVUE GROUP AG pharmaceutical preparations | 9.69M | 4.94% | 4.94% | $13.96B | May 14, 2025 | ▼ 250.0K |
TWO SEAS CAPITAL LP pharmaceutical preparations | 6.93M | 3.53% | 3.53% | $9.98B | May 15, 2025 | ▲ 700.0K |
MORGAN STANLEY pharmaceutical preparations | 6.59M | 3.36% | 3.36% | $9.48B | May 15, 2025 | ▲ 277.3K |
STATE STREET CORP pharmaceutical preparations | 4.55M | 2.32% | 2.32% | $6.55B | May 15, 2025 | ▲ 44.0K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 4.45M | 2.27% | 2.27% | $6.40B | May 13, 2025 | ▲ 106.3K |
MARSHALL WACE, LLP pharmaceutical preparations | 3.63M | 1.85% | 1.85% | $5.23B | May 15, 2025 | ▲ 3.63M |
NUVEEN, LLC pharmaceutical preparations | 3.09M | 1.57% | 1.57% | $4.45B | May 12, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
23
Increased
+8.47M shares2
New Positions
first time holders18
Decreased
−19.53M shares0
Sold Out
fully exitedNet shares change (top 50)
11.06M
+8.47M / −19.53M
Net new holders
+7
2 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ESPR insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
6
Buy transactions
4
Sell transactions
1.50
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
THOMPSON JOHN CRAIG director | May 28, 2026 | Award | 79,873 | — | — | 79.9K | Form 4 ↗ |
Shepard Jay director | May 28, 2026 | Award | 79,873 | — | — | 164.5K | Form 4 ↗ |
Hoffman Robert E. director | May 28, 2026 | Award | 79,873 | — | — | 85.2K | Form 4 ↗ |
Fischer Seth H. Z. director | May 28, 2026 | Award | 79,873 | — | — | 141.0K | Form 4 ↗ |
CARROLL J MARTIN director | May 28, 2026 | Award | 79,873 | — | — | 177.5K | Form 4 ↗ |
Looker Benjamin Chief Legal Officer | Mar 17, 2026 | Sale | 5,708 | $2.70 | $15.4K | 679.3K | Form 4 ↗ |
Koenig Sheldon L. President and CEO | Mar 17, 2026 | Sale | 25,578 | $2.72 | $69.5K | 2.17M | Form 4 ↗ |
Halladay Benjamin Chief Financial Officer | Mar 17, 2026 | Sale | 6,424 | $2.71 | $17.4K | 713.6K | Form 4 ↗ |
Looker Benjamin Chief Legal Officer | Mar 13, 2026 | Award | 300,840 | — | — | 685.1K | Form 4 ↗ |
Looker Benjamin Chief Legal Officer | Mar 13, 2026 | Award | 269,230 | $2.44 | $656.9K | 269.2K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Esperion Therapeutics, Inc. (ESPR) is primarily owned by institutional investors, who hold approximately 54.7% of total shares outstanding. Company insiders own approximately 0.00%, while retail and public investors account for the remaining 45.34%.
The largest institutional shareholder of Esperion Therapeutics, Inc. is BLACKROCK, INC., holding approximately 14.49 million shares — equal to 7.39% of outstanding shares — as of March 31, 2025.
A total of 191 institutional investors currently hold ESPR stock, with a combined institutional value of approximately $171,589,605 as of the most recent 13F filing period.
Frequently asked questions
ESPR ownershipEsperion Therapeutics, Inc. (ESPR) is primarily owned by institutional investors, who hold approximately 54.7% of shares. The largest shareholder is BLACKROCK, INC. with a 7.39% stake. Company insiders hold 0.00%. Data sourced from SEC Form 13F as of March 31, 2025.